3-Oxodapagliflozin as a potent and highly selective SGLT2 inhibitor for the treatment of type 2 diabetes
Crossref DOI link: https://doi.org/10.1007/s40242-014-4043-9
Published Online: 2014-09-05
Published Print: 2014-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Zhang, Shuo
Wang, Yuli
Liu, Wei
Xie, Yafei
Liu, Yuqiang
Xu, Weiren
Tang, Lida
Wang, Jianwu
Zhao, Guilong
Text and Data Mining valid from 2014-09-05